ticlopidine has been researched along with Aging in 9 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
Excerpt | Relevance | Reference |
---|---|---|
"In the PRODIGY trial, prolonging clopidogrel-based DAPT beyond six months in elderly patients increased the risk of bleeding, without affording a significant prevention of ischaemic events." | 5.24 | Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. ( Ariotti, S; Franzone, A; Gargiulo, G; Heg, D; Magnani, G; Marino, M; Piccolo, R; Santucci, A; Tebaldi, M; Valgimigli, M; Windecker, S, 2017) |
"In our present study we investigated the association between platelet aggregation in patients treated with the most widely used antiplatelet agents (100 and 300-325 mg acetylsalicylic acid (ASA), 75 mg clopidogrel, 500 mg ticlopidine and the combination of 100 mg aspirin and 75 mg clopidogrel), fibrinogen levels and aging." | 3.74 | Relation of platelet aggregation and fibrinogen levels to advancing age in aspirin- and thienopyridine-treated patients. ( Alexy, T; Feher, G; Horvath, B; Kenyeres, P; Kesmarky, G; Koltai, K; Lenart, I; Marton, Z; Toth, K, 2008) |
" There have been a limited number of studies investigating the pharmacokinetic profile of the drug." | 2.39 | Clinical pharmacokinetics of ticlopidine. ( Desager, JP, 1994) |
"High interindividual variability in clinical outcomes following clopidogrel's standard dosing regimen continues to be a challenge even two decades after its approval." | 1.46 | Identifying clinically relevant sources of variability: The clopidogrel challenge. ( Horenstein, RB; Jiang, XL; Lesko, LJ; Lewis, JP; Peletier, LA; Samant, S; Schmidt, S; Shuldiner, AR, 2017) |
" The longer t1/2,z and higher AUC values after multiple dosing probably reflect an increase in bioavailability of ticlopidine after repeated dosing, saturation of metabolism or insufficient analytical sensitivity to characterize the terminal elimination phase after single dose." | 1.28 | Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. ( Gabuzda, T; Massey, I; Molony, B; Shah, J; Teitelbaum, P, 1991) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (22.22) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 5 (55.56) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dupouy, P | 1 |
Pongas, D | 1 |
Rubimbura, V | 1 |
Labbe, R | 1 |
Sotirov, I | 1 |
Pernes, JM | 1 |
Samant, S | 1 |
Jiang, XL | 1 |
Peletier, LA | 1 |
Shuldiner, AR | 1 |
Horenstein, RB | 1 |
Lewis, JP | 1 |
Lesko, LJ | 1 |
Schmidt, S | 1 |
Piccolo, R | 1 |
Magnani, G | 1 |
Ariotti, S | 1 |
Gargiulo, G | 1 |
Marino, M | 1 |
Santucci, A | 1 |
Franzone, A | 1 |
Tebaldi, M | 1 |
Heg, D | 1 |
Windecker, S | 1 |
Valgimigli, M | 1 |
Caruthers, RL | 1 |
Dorsch, MP | 1 |
Koltai, K | 1 |
Feher, G | 1 |
Kenyeres, P | 1 |
Lenart, I | 1 |
Alexy, T | 1 |
Horvath, B | 1 |
Marton, Z | 1 |
Kesmarky, G | 1 |
Toth, K | 1 |
Yokoyama, T | 1 |
Usui, T | 1 |
Kiyama, K | 1 |
Nakashima, R | 1 |
Yukawa, N | 1 |
Kawabata, D | 1 |
Nojima, T | 1 |
Ohmura, K | 1 |
Fujii, T | 1 |
Mimori, T | 1 |
Tidjane, MA | 1 |
Voisin, S | 1 |
Lhermusier, T | 1 |
Bongard, V | 1 |
SiƩ, P | 1 |
CarriƩ, D | 1 |
Desager, JP | 1 |
Shah, J | 1 |
Teitelbaum, P | 1 |
Molony, B | 1 |
Gabuzda, T | 1 |
Massey, I | 1 |
2 reviews available for ticlopidine and Aging
Article | Year |
---|---|
Two cases of late-onset drug-induced lupus erythematosus caused by ticlopidine in elderly men.
Topics: Aged; Aged, 80 and over; Aging; Autoantibodies; Histones; Humans; Lupus Erythematosus, Systemic; Mal | 2010 |
Clinical pharmacokinetics of ticlopidine.
Topics: Adult; Aged; Aging; Animals; Bleeding Time; Blood Platelets; Cardiovascular Diseases; Drug Interacti | 1994 |
1 trial available for ticlopidine and Aging
Article | Year |
---|---|
Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Aspirin; Clopidogrel; Drug Therapy, Combination; Female | 2017 |
6 other studies available for ticlopidine and Aging
Article | Year |
---|---|
[A case review: About a STEMI in the very elderly].
Topics: Aged, 80 and over; Aging; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; A | 2015 |
Identifying clinically relevant sources of variability: The clopidogrel challenge.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Body Mass Index; Clopidogrel; Computer Simulatio | 2017 |
Letter by Caruthers and Dorsch regarding article, "Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the platelet inhibition in children on cLOpidogrel (PICOLO) trial".
Topics: Adolescent; Adult; Aging; Child; Child, Preschool; Clopidogrel; Cytochrome P-450 CYP3A; Dose-Respons | 2008 |
Relation of platelet aggregation and fibrinogen levels to advancing age in aspirin- and thienopyridine-treated patients.
Topics: Aged; Aging; Aspirin; Clopidogrel; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, C | 2008 |
More on: adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Aging; Angioplasty, Balloon, Coronary; Clopidogrel; | 2011 |
Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects.
Topics: Administration, Oral; Adult; Aged; Aging; Chromatography, Gas; Female; Half-Life; Humans; Male; Ticl | 1991 |